{"date":"2025-12-26","count":29,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6550-2025-12-26-2013-1ye5yun","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"20:13:09","subject":"公告本公司114年第二次股東臨時會重要決議事項","clause":"第18款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-12-26 20:13，「公告本公司114年第二次股東臨時會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-12-26-2012-s4zf0d","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"20:12:56","subject":"公告本公司董事會決議辦理現金增資私募普通股定價相關事宜","clause":"第11款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-12-26 20:12，「公告本公司董事會決議辦理現金增資私募普通股定價相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-12-26-2012-2wixgj","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"20:12:45","subject":"代子公司瑞華藥業(香港)有限公司公告董事解任","clause":"第6款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-12-26 20:12，「代子公司瑞華藥業(香港)有限公司公告董事解任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-12-26-2012-hcrns5","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"20:12:33","subject":"代重要子公司DesigneRx Pharmaceuticals, Inc.公告董事解任","clause":"第6款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-12-26 20:12，「代重要子公司DesigneRx Pharmaceuticals, Inc.公告董事解任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-12-26-2012-obt9d1","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"20:12:20","subject":"代重要子公司Polaris Pharmaceuticals Inc.公告董事更換","clause":"第6款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-12-26 20:12，「代重要子公司Polaris Pharmaceuticals Inc.公告董事更換」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-12-26-2012-en85i8","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"20:12:07","subject":"代重要子公司迪瑞藥業(成都)有限公司公告更換董事","clause":"第6款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-12-26 20:12，「代重要子公司迪瑞藥業(成都)有限公司公告更換董事」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-12-26-2011-fkzy5x","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"20:11:55","subject":"公告本公司訴訟及非訴訟代理人異動","clause":"第8款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-12-26 20:11，「公告本公司訴訟及非訴訟代理人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-12-26-2011-1vhu1xi","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"20:11:43","subject":"公告本公司發言人異動","clause":"第8款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-12-26 20:11，「公告本公司發言人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6550-2025-12-26-2011-1su03io","company_id":"6550","company":"北極星藥業-KY","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"20:11:28","subject":"公告本公司執行長異動","clause":"第8款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：北極星藥業-KY（6550），2025-12-26 20:11，「公告本公司執行長異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6939-2025-12-26-1851-1h039nn","company_id":"6939","company":"啟弘生技","market":"興櫃","industry":"生技醫療","date":"2025-12-26","time":"18:51:00","subject":"公告本公司董事長依董事會授權決定限制員工權利新股之增資基準日","clause":"第44款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：啟弘生技（6939），2025-12-26 18:51，「公告本公司董事長依董事會授權決定限制員工權利新股之增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6666-2025-12-26-1800-1egfkms","company_id":"6666","company":"羅麗芬-KY","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"18:00:49","subject":"公告本公司董事會通過重要決議","clause":"第51款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：羅麗芬-KY（6666），2025-12-26 18:00，「公告本公司董事會通過重要決議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6891-2025-12-26-1721-5rax5d","company_id":"6891","company":"樂迦再生","market":"興櫃","industry":"生技醫療","date":"2025-12-26","time":"17:21:11","subject":"公告本公司董事會決議員工認股權憑證轉換普通股增資基準日","clause":"第9款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：樂迦再生（6891），2025-12-26 17:21，「公告本公司董事會決議員工認股權憑證轉換普通股增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6461-2025-12-26-1714-1qton","company_id":"6461","company":"益得","market":"上櫃","industry":"生技醫療","date":"2025-12-26","time":"17:14:30","subject":"本公司董事會通過簽訂獨家授權經銷協議","clause":"第10款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：益得（6461），2025-12-26 17:14，「本公司董事會通過簽訂獨家授權經銷協議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6986-2025-12-26-1714-17cdwrd","company_id":"6986","company":"和迅","market":"上櫃","industry":"生技醫療","date":"2025-12-26","time":"17:14:26","subject":"因應本公司申請股票上櫃作業需求委託簽證會計師出具內控專審報告","clause":"第25款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：和迅（6986），2025-12-26 17:14，「因應本公司申請股票上櫃作業需求委託簽證會計師出具內控專審報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6827-2025-12-26-1702-1kknj4t","company_id":"6827","company":"巨生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-26","time":"17:02:06","subject":"公告本公司供查驗登記用MPB-1734用於罹患晚期實體腫瘤之第1/2a期臨床試驗計畫(計畫編號：DMB-CT-001)結案報告，經衛福部同意備查。","clause":"第8款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：巨生醫（6827），2025-12-26 17:02，「公告本公司供查驗登記用MPB-1734用於罹患晚期實體腫瘤之第1/2a期臨床試驗計畫(計畫編號：DMB-CT-001)結」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6857-2025-12-26-1700-p67uuk","company_id":"6857","company":"宏碁智醫","market":"興櫃","industry":"生技醫療","date":"2025-12-26","time":"17:00:09","subject":"公告本公司內部稽核主管異動","clause":"第11款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：宏碁智醫（6857），2025-12-26 17:00，「公告本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4167-2025-12-26-1646-isqttc","company_id":"4167","company":"松瑞藥","market":"上櫃","industry":"生技醫療","date":"2025-12-26","time":"16:46:41","subject":"公告本公司董事會重要決議事項","clause":"第53款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：松瑞藥（4167），2025-12-26 16:46，「公告本公司董事會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-12-26-1645-in3r67","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-12-26","time":"16:45:44","subject":"公告本公司董事會決議通過對100％投資之SAMOA子公司現金增資","clause":"第17款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-12-26 16:45，「公告本公司董事會決議通過對100％投資之SAMOA子公司現金增資」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6876-2025-12-26-1644-1ny40f9","company_id":"6876","company":"朗齊生醫*","market":"興櫃","industry":"生技醫療","date":"2025-12-26","time":"16:44:45","subject":"公告本公司董事會決議調整現金增資發行新股股數","clause":"第9款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：朗齊生醫*（6876），2025-12-26 16:44，「公告本公司董事會決議調整現金增資發行新股股數」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4169-2025-12-26-1626-mg6j0j","company_id":"4169","company":"泰宗","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"16:26:37","subject":"公告本公司董事會決議初次上市掛牌前辦理現金增資發行新股","clause":"第9款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：泰宗（4169），2025-12-26 16:26，「公告本公司董事會決議初次上市掛牌前辦理現金增資發行新股」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6838-2025-12-26-1612-1vqqdiw","company_id":"6838","company":"台新藥","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"16:12:03","subject":"公告本公司授權夥伴向南非衛生產品監管局(SAHPRA)申請眼部術後炎症和疼痛治療新藥APP13007上市查驗登記獲收件許可","clause":"第10款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：台新藥（6838），2025-12-26 16:12，「公告本公司授權夥伴向南非衛生產品監管局(SAHPRA)申請眼部術後炎症和疼痛治療新藥APP13007上市查驗登記獲收件許」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4169-2025-12-26-1605-12kb9nt","company_id":"4169","company":"泰宗","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"16:05:16","subject":"公告本公司董事會決議將「薪資報酬委員會」更名為「薪資報酬暨提名委員會」","clause":"第6款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：泰宗（4169），2025-12-26 16:05，「公告本公司董事會決議將「薪資報酬委員會」更名為「薪資報酬暨提名委員會」」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4169-2025-12-26-1604-mg6j0j","company_id":"4169","company":"泰宗","market":"上市","industry":"生技醫療","date":"2025-12-26","time":"16:04:23","subject":"公告本公司董事會決議初次上市掛牌前辦理現金增資發行新股","clause":"第9款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：泰宗（4169），2025-12-26 16:04，「公告本公司董事會決議初次上市掛牌前辦理現金增資發行新股」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3176-2025-12-26-1534-qmpqzy","company_id":"3176","company":"基亞","market":"上櫃","industry":"生技醫療","date":"2025-12-26","time":"15:34:24","subject":"開發中新藥OBP-301進度更新","clause":"第53款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：基亞（3176），2025-12-26 15:34，「開發中新藥OBP-301進度更新」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4168-2025-12-26-1533-1vdvyhc","company_id":"4168","company":"醣聯","market":"上櫃","industry":"生技醫療","date":"2025-12-26","time":"15:33:36","subject":"公告本公司董事會決議通過子公司辦理解散清算","clause":"第53款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：醣聯（4168），2025-12-26 15:33，「公告本公司董事會決議通過子公司辦理解散清算」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7851-2025-12-26-1530-129kdkl","company_id":"7851","company":"慧康生技*-KY","market":"興櫃","industry":"生技醫療","date":"2025-12-26","time":"15:30:38","subject":"本公司依「公開發行公司資金貸與及背書保證處理準則」第二十二條第一項第二款及第三款之規定辦理公告","clause":"第20款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：慧康生技*-KY（7851），2025-12-26 15:30，「本公司依「公開發行公司資金貸與及背書保證處理準則」第二十二條第一項第二款及第三款之規定辦理公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7851-2025-12-26-1529-1gxckxu","company_id":"7851","company":"慧康生技*-KY","market":"興櫃","industry":"生技醫療","date":"2025-12-26","time":"15:29:57","subject":"本公司依「公開發行公司資金貸與及背書保證處理準則」第二十二條第一項第一款之規定辦理公告","clause":"第20款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：慧康生技*-KY（7851），2025-12-26 15:29，「本公司依「公開發行公司資金貸與及背書保證處理準則」第二十二條第一項第一款之規定辦理公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3205-2025-12-26-1451-f0dsjp","company_id":"3205","company":"佰研","market":"上櫃","industry":"生技醫療","date":"2025-12-26","time":"14:51:14","subject":"公告本公司董事會通過解除新任總經理競業禁止之限制","clause":"第21款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：佰研（3205），2025-12-26 14:51，「公告本公司董事會通過解除新任總經理競業禁止之限制」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3205-2025-12-26-1450-q1wnzv","company_id":"3205","company":"佰研","market":"上櫃","industry":"生技醫療","date":"2025-12-26","time":"14:50:29","subject":"公告本公司董事會通過總經理異動案","clause":"第6款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：佰研（3205），2025-12-26 14:50，「公告本公司董事會通過總經理異動案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}